SCHEMBL2056485

SCHEMBL2056485

CCC(=O)Nc1ccc(CF)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.58
MAPT P10636 2/20 0.58
ATM Q13315 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.56
RAB9A P51151 4/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
NPC1 O15118 1/20 0.53
TP53 P04637 1/20 0.53
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 2/20 0.51
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13989319 0.85 GAA (0.73) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL12285463 0.84 GAA (0.61) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL826066 0.84 HDAC3 (0.64) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL13652580 0.82 GAA (0.59) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL6029960 0.82 GAA (0.59) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL14509045 0.81 SMN1; SMN2 (0.50) GAAATMSMN1; SMN2RAB9AALDH1A1
SCHEMBL1189878 0.81 CA12 (0.59) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL31325579 0.81 GAA (0.58) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL2642613 0.81 GAA (0.58) GAAMAPTATMSMN1; SMN2RAB9A
SCHEMBL10117151 0.81 POLB (0.60) GAAMAPTATMSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 GAA 3982/4885MAPT 4299/4885ATM 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.